SMT201300093B - Formulazioni di vwf ricombinante liofilizzate - Google Patents

Formulazioni di vwf ricombinante liofilizzate

Info

Publication number
SMT201300093B
SMT201300093B SM201300093T SM201300093T SMT201300093B SM T201300093 B SMT201300093 B SM T201300093B SM 201300093 T SM201300093 T SM 201300093T SM 201300093 T SM201300093 T SM 201300093T SM T201300093 B SMT201300093 B SM T201300093B
Authority
SM
San Marino
Prior art keywords
lyophilized recombinant
formulations
recombinant vwf
rvwf
vwf formulations
Prior art date
Application number
SM201300093T
Other languages
English (en)
Inventor
Kurt Schnecker
Eva Haidweger
Peter Turecek
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42109151&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201300093(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Publication of SMT201300093B publication Critical patent/SMT201300093B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
SM201300093T 2008-10-21 2013-08-16 Formulazioni di vwf ricombinante liofilizzate SMT201300093B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10727308P 2008-10-21 2008-10-21
PCT/US2009/061470 WO2010048275A2 (en) 2008-10-21 2009-10-21 Lyophilized recombinant vwf formulations

Publications (1)

Publication Number Publication Date
SMT201300093B true SMT201300093B (it) 2013-11-08

Family

ID=42109151

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201300093T SMT201300093B (it) 2008-10-21 2013-08-16 Formulazioni di vwf ricombinante liofilizzate

Country Status (21)

Country Link
US (4) US20100099603A1 (it)
EP (2) EP2601932A1 (it)
JP (6) JP5781931B2 (it)
KR (2) KR101953494B1 (it)
CN (2) CN102387784B (it)
AR (2) AR074054A1 (it)
AU (1) AU2009307648C1 (it)
BR (1) BRPI0919693A2 (it)
CA (1) CA2740919A1 (it)
CY (1) CY1113869T1 (it)
DK (1) DK2349314T3 (it)
ES (1) ES2409032T3 (it)
HR (1) HRP20130414T1 (it)
MX (1) MX2011004247A (it)
NZ (1) NZ592704A (it)
PL (1) PL2349314T3 (it)
PT (1) PT2349314E (it)
SI (1) SI2349314T1 (it)
SM (1) SMT201300093B (it)
TW (3) TWI593421B (it)
WO (1) WO2010048275A2 (it)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2740919A1 (en) * 2008-10-21 2010-04-29 Baxter International Inc. Lyophilized recombinant vwf formulations
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
AU2011316111B2 (en) 2010-10-12 2015-05-28 Merz Pharma Gmbh & Co. Kgaa Formulation suitable for stabilizing proteins, which is free of mammalian excipients
EP2717905B1 (en) * 2011-06-10 2018-05-23 Baxalta GmbH Treatment of coagulation disease by administration of recombinant vwf
EP2698162A1 (en) * 2012-08-15 2014-02-19 Credentis AG Method for producing a composition for treating a tooth lesion
WO2014141149A1 (en) * 2013-03-15 2014-09-18 Glaxosmithkline Intellectual Property (No.2) Limited Formulations with reduced viscosity
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
CN106414719B (zh) 2014-06-13 2020-02-14 杰特有限公司 生物反应器中重组von Willebrand因子的改进生产
AU2016225111B2 (en) * 2015-02-27 2021-12-09 Board Of Regents, The University Of Texas System Polypeptide therapeutics and uses thereof
BE1023343B1 (nl) * 2015-05-20 2017-02-09 Mycartis Nv Opslagbuffer
JP7307047B2 (ja) 2017-07-07 2023-07-11 武田薬品工業株式会社 組換えｖｗｆの投与による重度のフォンヴィレブランド病を患う患者における消化管出血の治療
AU2018298232A1 (en) 2017-07-07 2020-01-30 Takeda Pharmaceutical Company Limited Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant VWF
EP3672644A1 (en) 2017-08-23 2020-07-01 CSL Behring GmbH Method for virus filtration of von willebrand factor
WO2019183290A1 (en) 2018-03-21 2019-09-26 Baxalta Incorporated Separation of vwf and vwf propeptide by chromatographic methods
WO2020055812A1 (en) 2018-09-10 2020-03-19 Lung Therapeutics, Inc. Modified peptide fragments of cav-1 protein and the use thereof in the treatment of fibrosis
BR112021015068A2 (pt) 2019-02-01 2021-10-05 Takeda Pharmaceutical Company Limited Métodos de tratamento profilático usando vwf recombinante (rvwf)
EP4028046B1 (en) 2019-09-11 2024-02-14 Takeda Pharmaceutical Company Limited Methods of treatment related to complexes of von willebrand factor and complement c1q
AU2021216945A1 (en) 2020-02-04 2022-09-01 Takeda Pharmaceutical Company Limited Treatment of menorrhagia in patients with severe von Willebrand Disease by administration of recombinant VWF
CN111789867B (zh) * 2020-08-27 2022-01-11 中国人民解放军军事科学院军事医学研究院 一种适用于提高血浆干粉功能的适配液
JP7371208B2 (ja) * 2022-01-19 2023-10-30 Ｋｍバイオロジクス株式会社 ｖｏｎ Ｗｉｌｌｅｂｒａｎｄ因子含有製剤
WO2023170680A1 (en) 2022-03-08 2023-09-14 Equashield Medical Ltd Fluid transfer station in a robotic pharmaceutical preparation system

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941763A (en) * 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US8597910B1 (en) 1985-04-11 2013-12-03 Children's Medical Center Corporation DNA encoding Von Willebrand Factor (VWF) and methods and cells for producing VFW, and VFW produced by the DNA, methods and cells
WO1986006096A1 (en) 1985-04-11 1986-10-23 The Children's Medical Center Corporation Von willebrand factor
US5900476A (en) 1986-05-30 1999-05-04 The Scripps Research Institute Therapeutic domains of van Willebrand factor
US5201033A (en) 1990-01-17 1993-04-06 International Business Machines Corporation Method for controlling cursor movements on certain computer workstations
AU2253392A (en) * 1991-06-20 1993-01-25 Rhone-Poulenc Rorer International (Holdings) Inc. Therapeutic fragments of von willebrand factor
US5847086A (en) 1991-06-20 1998-12-08 Centeon L.L.C. Therapeutic fragments of von Willebrand factor
US5670132A (en) * 1994-09-20 1997-09-23 Immunomedics, Inc. Modified radioantibody fragments for reduced renal uptake
DE4435392B4 (de) * 1994-10-04 2008-02-07 Immuno Ag Verfahren zur Trennung von vWF in hochmolekularen vWF und niedermolekularen vWF
DE4435485C1 (de) * 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
US20010046487A1 (en) 1994-12-30 2001-11-29 Roser Bruce J. Methods for loading platelets, stabilizing platelets for dry storage and compositions obtained thereby
US7244824B2 (en) * 1995-01-19 2007-07-17 Quadrant Drug Delivery Limited Dried blood factor composition comprising trehalose
GB9501040D0 (en) 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US7253262B2 (en) * 1995-01-19 2007-08-07 Quandrant Drug Delivery Limited Dried blood factor composition comprising trehalose
IL122910A (en) 1995-07-27 2002-05-23 Genentech Inc Stable isotonic protein formulation that has undergone lyophilization
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6005077A (en) * 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
US5925738A (en) * 1995-12-01 1999-07-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
AT403764B (de) * 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
DE69734247T2 (de) * 1996-07-19 2006-06-22 The Regents Of The University Of Michigan, Ann Arbor Für den von willebrand faktor der hunde kodierende dna und verfahren zu ihrer verwendung
SE9604296D0 (sv) 1996-11-22 1996-11-22 Astra Ab New pharmaceutical formulation of polypeptides
US20020019036A1 (en) 1996-12-13 2002-02-14 Hans-Peter Schwarz Von willebrand factor derivatives and methods of isolating proteins that bind to von willebrand factor
AT405740B (de) * 1996-12-13 1999-11-25 Immuno Ag Von willebrand-faktor-derivat sowie ein verfahren zur isolierung von proteinen
AT405403B (de) * 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
AT406373B (de) 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
AT405485B (de) * 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
US6005007A (en) * 1997-07-18 1999-12-21 Farmer; Luc J. Retinoids, methods for their production and use
US6310183B1 (en) * 1997-09-10 2001-10-30 Novo Nordisk A/S Coagulation factor VIIa composition
US6531577B1 (en) 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
EP1148063A1 (de) 2000-04-18 2001-10-24 Octapharma AG Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung
US20040038878A1 (en) * 2000-08-04 2004-02-26 Masahiko Tanikawa Injectable protein formulations
ES2644275T3 (es) 2000-08-11 2017-11-28 Chugai Seiyaku Kabushiki Kaisha Preparaciones estabilizadas que contienen anticuerpos
DE10043124A1 (de) * 2000-08-31 2002-03-14 Max Delbrueck Centrum Verfahren zur Diagnostik von neuronalen Erkrankungen sowie zur Behandlung der defizienten primären Hämostase
JP4477299B2 (ja) 2000-10-02 2010-06-09 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 因子ｖｉｉグリコ型
PT1324776E (pt) * 2000-10-12 2009-12-23 Genentech Inc Formulações de proteína concentradas de viscosidade reduzida
UA86744C2 (en) 2002-06-21 2009-05-25 Ново Нордиск Хэлс Кеа Аг Pegylated factor vii glycoforms
WO2004039337A2 (en) 2002-10-31 2004-05-13 Protein Design Labs, Inc. Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization
ES2229931B1 (es) 2003-10-03 2006-01-16 Grifols, S.A. Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.
FR2861395B1 (fr) 2003-10-23 2006-02-17 Lab Francais Du Fractionnement Facteur viii viralement securise a faible teneur en multimeres superieurs
DK2298287T3 (en) * 2003-12-19 2018-07-23 Novo Nordisk Healthcare Ag Stabilized compositions of factor VII polypeptides
US20060008415A1 (en) * 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins
FR2874216B1 (fr) * 2004-08-16 2006-11-03 Lab Francais Du Fractionnement Procede de preparation d'un concentre de facteur von willebrand (fvw) par voie chromatographique et concentre de fvw susceptible d'etre ainsi obtenu
DE102004044421B4 (de) * 2004-09-14 2010-06-24 Biotest Ag Verfahren zur Trennung eines von Willebrand Faktors mit einer spezifischen VWF-Aktivität von wenigstens 50 E/mg VWF-Antigen von einem von Willebrand Faktor mit niedriger Aktivität und Verwendung von Hydroxylapatit dafür
DK1835938T3 (da) * 2004-12-27 2013-11-04 Baxter Int Polymer-von Willebrand-faktor-konjugater
EP1707634A1 (en) * 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
GB0509443D0 (en) * 2005-05-09 2005-06-15 Prometic Biosciences Ltd Affinity adsorbents for factor VIII and von willebrand's factor
EP1899462B1 (en) * 2005-07-02 2011-03-09 Arecor Limited Stable aqueous systems comprising proteins
US7956160B2 (en) * 2005-07-22 2011-06-07 Amgen Inc. Concentrated protein lyophilates, methods, and uses
PT1986612E (pt) * 2006-02-07 2012-11-06 Shire Human Genetic Therapies Composição estável de glucocerebrosidase
GB0700523D0 (en) * 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
US7559509B1 (en) 2007-02-12 2009-07-14 Thomas C. Taylor Large cryogenic tank logistics for in-space vehicles
WO2008127654A2 (en) * 2007-04-11 2008-10-23 The University Of North Carolina At Chapel Hill Methods and compositions for intra-articular coagulation proteins
JP5401446B2 (ja) * 2007-04-26 2014-01-29 バイエル ヘルスケア エルエルシー 凍結貯蔵を目的とした、組み換えタンパク質溶液の安定化
PL2167117T3 (pl) * 2007-06-13 2013-01-31 Csl Behring Gmbh Zastosowanie stabilizowanego VWP preparatu FVIII do podawania pozanaczyniowego w terapii i profilaktyce zaburzeń krzepliwości krwi
FR2920429B1 (fr) * 2007-08-30 2012-10-05 Lfb Biotechnologies Procede de purification du facteur viii et du facteur von willebrand
TW201731488A (zh) * 2007-12-28 2017-09-16 巴克斯歐塔公司 重組ｖｗｆ調配物
ES2298096B1 (es) 2008-01-08 2009-01-01 Grifols, S.A. Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos.
DE102008032361A1 (de) * 2008-07-10 2010-01-21 Csl Behring Gmbh Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie
CN104013569A (zh) * 2008-10-15 2014-09-03 精达制药公司 高浓缩药物颗粒、制剂、混悬剂及其应用
CA2740919A1 (en) * 2008-10-21 2010-04-29 Baxter International Inc. Lyophilized recombinant vwf formulations
KR20110093775A (ko) * 2008-11-03 2011-08-18 바이엘 헬스케어 엘엘씨 혈우병 치료 방법
EP2393501A1 (en) * 2009-02-05 2011-12-14 Pierre Philippart Method and means for producing tissues and tissues obtained
SG178478A1 (en) * 2009-08-20 2012-04-27 Baxter Int Purification of vwf for increased removal of non-lipid enveloped viruses

Also Published As

Publication number Publication date
CA2740919A1 (en) 2010-04-29
CN102387784B (zh) 2014-04-02
AR074054A1 (es) 2010-12-22
US10232022B2 (en) 2019-03-19
MX2011004247A (es) 2011-05-25
JP2018199715A (ja) 2018-12-20
JP2012506387A (ja) 2012-03-15
JP7003183B2 (ja) 2022-02-04
AR118012A2 (es) 2021-09-08
US20210315979A9 (en) 2021-10-14
KR101953494B1 (ko) 2019-02-28
JP2016106124A (ja) 2016-06-16
JP2020143166A (ja) 2020-09-10
TWI508735B (zh) 2015-11-21
WO2010048275A3 (en) 2011-09-15
EP2601932A1 (en) 2013-06-12
HRP20130414T1 (en) 2013-06-30
US20130172269A1 (en) 2013-07-04
AU2009307648C1 (en) 2016-12-08
CY1113869T1 (el) 2016-10-05
ES2409032T3 (es) 2013-06-24
TWI670072B (zh) 2019-09-01
JP5781931B2 (ja) 2015-09-24
US20100099603A1 (en) 2010-04-22
TWI593421B (zh) 2017-08-01
US11191813B2 (en) 2021-12-07
US20190142908A1 (en) 2019-05-16
AU2009307648A1 (en) 2010-04-29
JP6425674B2 (ja) 2018-11-21
US20160129090A1 (en) 2016-05-12
BRPI0919693A2 (pt) 2020-08-11
WO2010048275A2 (en) 2010-04-29
CN103919736A (zh) 2014-07-16
TW201021825A (en) 2010-06-16
EP2349314A2 (en) 2011-08-03
CN102387784A (zh) 2012-03-21
TW201722459A (zh) 2017-07-01
KR20110088523A (ko) 2011-08-03
NZ592704A (en) 2013-02-22
KR101772674B1 (ko) 2017-09-01
DK2349314T3 (da) 2013-05-27
EP2349314B1 (en) 2013-02-27
SI2349314T1 (sl) 2013-05-31
AU2009307648B2 (en) 2015-09-24
PT2349314E (pt) 2013-05-28
JP2022037215A (ja) 2022-03-08
TW201509429A (zh) 2015-03-16
KR20170049636A (ko) 2017-05-10
PL2349314T3 (pl) 2013-07-31
JP2014133758A (ja) 2014-07-24

Similar Documents

Publication Publication Date Title
SMT201300093B (it) Formulazioni di vwf ricombinante liofilizzate
WO2009086400A3 (en) Recombinant vwf formulations
CY1118038T1 (el) Λυοφιλισμενες φαρμακοτεχνικες μορφες θεραπευτικου πεπτισωματος
CY1120994T1 (el) Καινοτομες συνθεσεις διαλυματος που περιεχουν κυτταρικο παραγοντα και χρηση αυτων για τη θεραπεια τραυματων
ATE464902T1 (de) Stabile pharmazeutische zubereitungen von montelukast-natrium
DOP2006000025A (es) Agonistas de pyy y sus usos
BRPI0606687A2 (pt) composições nutracêuticas
CY1115413T1 (el) Ανασυνδυασμενη fsh η οποια περιλαμβανει αλφα 2,3- και αλφα 2',6-sialylation
CY1117727T1 (el) Φαρμακευτικες συνθεσεις κλωστηριδιακης τοξινης σταθεροποιημενης χωρις πρωτεϊνη
EA201590525A1 (ru) Слитые белки для лечения метаболического синдрома
CL2007001185A1 (es) Formulaciones que estabilizan o inhiben la agregacion inducida por silicona de un conjugado de polisacarido-proteina;formulaciones que estabilizan o inhiben la agregacion inducida por silicona de un conjugado de polisacarido-proteina;formulaciones que estabilizan o inhiben la agregacion inducida por silicona de una composicion de proteina de n meningitidis
EA200701065A1 (ru) Инъецируемые составы, содержащие нанодисперсный оланзапин
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
LU91989I2 (fr) Bydureon
AR070690A1 (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf (factor de crecimiento de fibroblastos)
ATE537844T1 (de) Dauerhafte lokalanästhetische zusammensetzung mit saib
CL2010001346A1 (es) Polipeptido mutante del factor de crecimiento de fibroblastos (fgf); multimero que comprende dos o mas copias del polipeptido de fusion antes mencionado; composicion farmaceutica que comprende el polipeptido.
AR113422A2 (es) Agentes tensioactivos reconstituidos que tienen propiedades mejoradas
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
CL2011000713A1 (es) Composicion farmaceutica antiparasitaria oral subtoxica de imidacloprid para el control sistemico de parasitos hematofagos.
CR10124A (es) Formulaciones orales que comprenden tigeciclina
AR054739A1 (es) Composicion de liberacion sostenida de droga proteica
CO6400198A2 (es) Composiciones y metodos novedosos
EA200601596A1 (ru) Улучшенный состав 6-меркаптопурина
ATE452646T1 (de) Zusammensetzungen mit epigallocatechingallat und proteinhydrolysat